Advertisement · 728 × 90
#
Hashtag
#cvLipids
Advertisement · 728 × 90
Post image

Essence-CTA: Does Olezarsen Reduce Noncalcified Coronary Plaque Volume?

Check out the results of the 🆕 #ACC26 late-breaking clinical trial: https://bit.ly/4tc0UKH #cvLipids #CardioSky

2 2 0 2
Post image

Elevated Lp(a) doesn't just raise #CV risk, it carries a major economic price tag. Data shared by @nishantshahmd.bsky.social at #ACC26 shows the highest Lp(a) group incurs $506/person/year or $253M over 5 years, in indirect costs. The case for early testing is clear. #ASCVD #cvLipids #CardioSky

0 0 0 0
Preview
What You Should Know about New Cholesterol Guidelines for 2026 NBC medical reporter Dr. Akshay Syal joins TODAY to break down what cholesterol is, why it matters and what has changed — including a younger age for treatment, a coronary calcium score to test for he...

Featured on the @todayshow.com: @nbcnews.com medical reporter Dr. Akshay Syal discusses @accintouch.bsky.social and @americanheart.bsky.social's new guideline for managing #cvLipids and #Cholesterol.

📺Watch the video: on.today.com/4lFVuVY #JACC

0 0 0 0
Post image

The 2026 ACC/AHA Multisociety #Dyslipidemia Guideline-at-a-Glance offers a visual summary of key updates in CV risk assessment, lipid treatment goals, & #ASCVD risk reduction.

A quick reference for clinicians: https://bit.ly/4rGIMHY

#JACC #ClinicalGuidelines #cvLipids #CardioSky

1 2 0 0
Post image

🆕 ACC/AHA Guideline on the Management of Dyslipidemia offers a comprehensive “one-stop shop” for addressing the evaluation, management & monitoring of individuals w/ dyslipidemias.

Read the full guideline in #JACC: https://bit.ly/4cLB0J0 #cvLipids #ClinicalGuidelines #CardioSky #MedSky

4 4 0 1
Post image

ACC/AHA & 9 other leading medical associations released an updated clinical guideline for managing #dyslipidemia. About 1 in 4 US adults has high LDL-C, raising risk of heart attack & stroke.

Get the details in #JACC: https://bit.ly/4cLB0J0

#ClinicalGuidelines #cvLipids #ASCVD #CardioSky

6 3 0 0
Preview
Reducing Saturated Fat May Reduce Mortality, NFMI, Stroke in High-Risk Individuals - American College of Cardiology Reducing saturated fat, especially replacing it with PUFA, may lower mortality, NFMI, and stroke risk in high-risk adults.

Among individuals w/ an elevated baseline cardiovascular risk, reducing the intake of saturated fatty acid was associated w/ a lower risk of mortality, nonfatal myocardial infarction and stroke over five years.

Read the journal scan for more: https://bit.ly/452T64u #cvLipids #CardioSky #MedSky

0 0 2 0
Video

#AHA25: ACC Vice President Roxana Mehran, MD, FACC, shares insights on groundbreaking cardiometabolic therapeutic trials, including highlights from the VESALIUS-CV study.

Get the full details here: https://bit.ly/4oBNohQ

#cvPrev #cvLipids #ACCAnywhere #CardioSky #MedSky

2 2 0 0
Post image

CRISPR-Cas9 ➡️ First-in-Human trial presented at #AHA25 suggests one-time infusion of an investigational CRISPR-Cas9 therapy targeting ANGPTL3 is safe & can reduce both LDL cholesterol & triglycerides.

Read the ACC News Story for more: https://bit.ly/47Nfb7O

#cvLipids #CardioSky #MedSky

2 2 0 0
Post image

A 🆕 ACC Scientific Statement on Inflammation & #CVD highlights new groundbreaking research linking inflammation #ASCVD & provides consensus-based recommendations for evaluation, treatment & prevention reflecting this new era.

Learn more: https://bit.ly/4nUui5w #cvLipids #CardioSky #MedSky #JACC

4 4 0 0
Post image

Young adults with high remnant cholesterol face significantly increased CV risk, even with optimal LDL-C. Findings from a 4.3M nationwide cohort highlight remnant-C as a potent, age-sensitive risk factor needing early preventive strategies. https://bit.ly/46KV4aP

#JACC #ASCVD #cvLipids #ACCIntl

1 3 0 0
Post image

In this pooled analysis of 2 phase 3 clinical trials, obicetrapib treatment was associated with a reduction in coronary events, evident beyond 6 months of treatment. https://bit.ly/47ljrwK

#JACC #ESCCongress #WCCardio #CVD #MACE #cvLipids

1 2 0 0
Preview
Overweight, Obesity in Patients With HeFH Contribute to Higher ASCVD Risk - American College of Cardiology

Overweight & obesity are common in patients with HeFH and are associated with a greater risk of #ASCVD starting in childhood and regardless of LDL-C level and lipid-lowering medication.

Read more: bit.ly/40IL3b3

#CardioSky #MedSky #cvLipids

6 4 0 0